The reclassification of noninvasive follicular variant of papillary thyroid carcinoma as noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) has created diagnostic and management issues for thyroid fine-needle aspiration (FNA). In response to these challenges, the authors' laboratory adopted a NIFTP policy including 1) stringent criteria (requiring pseudo-inclusions, papillae, and/or psammoma bodies) for a malignant diagnosis of papillary carcinoma to limit false-positive results due to NIFTP and 2) the use of explanatory notes in cases with cytomorphologic features suggestive of possible NIFTP to encourage lobectomy over thyroidectomy. This study examined the effects of this policy on FNA classification and subsequent surgical management. METHODS: All thyroid FNAs performed at Brigham and Women's Hospital (n 5 1300) during a 1-year period were evaluated for changes in the use of diagnostic categories, explanatory NIFTP notes, and surgical follow-up in comparison with historical controls. RESULTS: The use of specific Bethesda categories did not significantly change. Only a single case of NIFTP was mistakenly classified as malignant.
INTRODUCTION
The term noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) has replaced noninvasive follicular variant of papillary thyroid carcinoma (FVPTC) because of the indolent clinical course of such tumors. 1 Diagnostic criteria for NIFTP include a well-circumscribed/encapsulated tumor with a follicular growth pattern and nuclear features of papillary thyroid carcinoma (PTC). Cases with lymphovascular or capsular invasion, psammoma bodies, necrosis, significant mitotic activity, or morphologic features of other variants of PTC are excluded from the diagnosis. 1 To evaluate these parameters, complete excision of the nodule and microscopic examination of the entire periphery of the lesion are required. Because of the indolent nature of this tumor, total thyroidectomy or treatment with radioactive iodine is rarely indicated, potentially offering significant reductions in health care costs and patient morbidity with the reclassification of noninvasive FVPTC as NIFTP. Fine-needle aspiration (FNA) is the most common method for determining the management of a patient with a thyroid nodule, 2 and the reporting of thyroid FNA has been standardized with The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC). 3 An update to TBSRTC is expected shortly 4 ; the original version briefly addressed FVPTC 5 but predated the introduction of NIFTP. Given the substantial proportion of carcinomas (estimated at 20%) that will lose their moniker of malignancy, 1 our group and others have demonstrated that the risk of malignancy (ROM) in all Bethesda categories is anticipated to drop accordingly. 6, 7 These reductions are predicted to be most significant in the "indeterminate" diagnostic categories because historically the majority of NIFTP cases have been classified into these categories (Bethesda categories III-V). [6] [7] [8] The clinical import of recognizing potential NIFTP cases on FNA is most significant in the suspicious for malignancy (SUS) and malignant categories of TBSRTC. In contrast to patients with nodules interpreted as atypia of undetermined significance/follicular lesion of undetermined significance (AUS) or as suspicious for a follicular neoplasm/follicular neoplasm (SFN), patients with a SUS diagnosis are more frequently treated with initial total thyroidectomy because of the historically high ROM (60%-75%) 3 associated with this category. Similarly, the high predictive value of a malignant cytologic diagnosis has led most patients with a conclusive ("malignant") diagnosis of PTC to undergo total thyroidectomy. Although the introduction of NIFTP terminology is expected to only slightly diminish the ROM of the malignant category (from 99% to 94%-96%), 6, 7 this potential decrease is distressing to patients, clinicians, and cytopathologists alike because it increases the likelihood of a false-positive FNA result with corresponding overtreatment (total thyroidectomy vs lobectomy). Thus, in the NIFTP era, the recognition of cytomorphologic features that reliably distinguish a potential NIFTP from invasive FVPTC or classic PTC is desirable to promote more limited surgical intervention. A number of investigators have now characterized the cytomorphologic features associated with NIFTP. By definition, NIFTP has a follicular architecture and cells exhibiting some nuclear features of PTC. These subtle nuclear features overlap with those of both benign thyroid nodules and invasive FVPTC, resulting in the frequent classification of NIFTPs in the indeterminate Bethesda categories and precluding definitive diagnosis in cytologic material. Compared with classic PTC, NIFTPs typically lack features more frequently seen in malignant aspirates, such as nuclear pseudo-inclusions, papillae, and psammoma bodies. 9, 10 The prospective identification of these cytomorphologic features can distinguish potential NIFTP from classic PTC in most instances, particularly in aspirates for which a malignant diagnosis is being considered. 11 Therefore, we believe that attention to these features can help minimize the classification of potential NIFTP cases as malignant and promote more appropriate and conservative surgical management of such cases by lobectomy. In May 2016, in response to these observations on the introduction of NIFTP and after consultation with our clinical colleagues, our laboratory adopted a slightly modified approach to thyroid FNA diagnosis. We subsequently published our provisional approach for other laboratories to consider in their own clinical practice. 12 The approach remains true to the original framework of TBSRTC and applies only to the SFN, SUS, and malignant categories.
The new policy has 2 major components: 1. We recommend that pathologists limit the malignant for PTC diagnosis to cases with nuclear features of PTC and at least 1 of the following: frequent (3 or more) nuclear pseudo-inclusions, true papillae, and/or psammoma bodies.
2. Explanatory notes (termed NIFTP notes) are provided with the subset of SFN or SUS FNA diagnoses with features suggesting the possibility of NIFTP: nuclear features of PTC with a microfollicular architecture and a lack of frequent (3 or more) nuclear pseudo-inclusions, true papillae, or psammoma bodies.
Finally, an optional educational note describing the potential decrease in ROM due to the introduction of NIFTP was also offered for use with malignant for PTC cases.
Although we expected no significant changes in patient management with the addition of the NIFTP note for the subset of cases in the SFN category-lobectomy being the usual management with or without such a note 2 -we hoped that the NIFTP note would favorably alter patient management for cases in the SUS category. Others have endorsed explanatory notes for potential NIFTP cases, 13 but the concern has been expressed that the proposal to adopt refined criteria for a malignant for PTC diagnosis may be "too hasty" and could drastically alter thyroid FNA classification. 14 Therefore, in this study, we examined the effect that our modified policy has had in the 1-year period since its implementation on both cytologic diagnoses and subsequent surgical management.
MATERIALS AND METHODS
This study was approved by the institutional review board of the Brigham and Women's Hospital. The study cohort consisted of all thyroid FNA specimens identified in the laboratory database during the 1-year period beginning in May 2016, the month in which we implemented a revised policy in response to NIFTP (1300 cases). This full policy emphasized frequent consultation and the review of cases at our weekly cytology conference to build a consensus for cases of suspected NIFTP. No changes were made in the use of the nondiagnostic (ND), benign, and AUS categories. For cases classified as SFN with borderline nuclear features of PTC, an explanatory note suggesting the possibility of NIFTP was added. For cases believed to be SUS with more pronounced features of PTC that lacked frequent nuclear pseudo-inclusions, true papillae, or psammoma bodies, an explanatory note raising the possibility of NIFTP was included with the case. Finally, the policy also proposed modifications to the use of the malignant category to attempt to exclude cases of NIFTP by emphasizing the identification of frequent pseudo-inclusions (3), true papillae, or psammoma bodies.
A control cohort from a 1-year period beginning in May 2014 (1353 cases) was selected to avoid overlap with a prospective study evaluating the ability of cytopathologists to identify morphologic features that suggest NIFTP. FNAs were performed by an endocrinologist with ultrasound guidance, as described previously, 15 and a single Papanicolaou-stained ThinPrep slide (Hologic, Marlborough, Massachusetts) was prepared for routine cytologic evaluation. Nine cytopathologists evaluated thyroid FNA specimens during the control period, and 10 during the study period. These 10 cytopathologists included the 9 from the control time period. All cases were classified according to TBSRTC: ND, benign, AUS, SFN, suspicious for a H€ urthle cell neoplasm (HUR), SUS, or malignant. All cytology reports were manually reviewed for the use of NIFTP notes in the study cohort or for the mention of cytologic features of FVPTC in the control cohort. Surgical follow-up data were retrieved from the laboratory information system, and all histopathology reports were reviewed and correlated with the preoperative FNA. All cases using an explanatory NIFTP note were reviewed and correlated with surgical pathology results. Similarly, all FNA specimens from patients with a subsequent diagnosis of NIFTP were also reviewed. All statistical analyses were performed with GraphPad Prism 5.02 (GraphPad Software, La Jolla, California). Comparisons between groups were performed with the chi-square test. Results were considered statistically significant at P .05.
RESULTS
The distribution of diagnostic categories for the study and control groups is summarized in Table 1 and Figure 1 . There were 1300 thyroid FNAs from the study period: 110 (8.5%) were ND, 850 (65%) were benign, 165 (13%) were AUS, 43 (3.3%) were SFN, 37 (2.8%) were HUR, 29 (2.2%) were SUS, and 66 (5.1%) were malignant. In comparison, in the control cohort of 1353 cases 113 (8.4%) were ND, 911 (67%) were benign, 161 (12%) were categorized as AUS, 38 (2.8%) were SFN, 28 (2.1%) were HUR, 32 (2.4%) were SUS, and 70 (5.2%) were categorized as malignant. There was no significant difference in the overall use of Bethesda categories after the adoption of the NIFTP policy (P 5 .81; v 2 5 3.0).
In our laboratory, before the introduction of the NIFTP note, when cytomorphology suggestive of FVPTC was apparent (predominantly a microfollicular architecture, nuclear features of PTC, a lack of true papillae, and psammoma bodies), some cytopathologists would note the presence of features of FVPTC. During the control time period, such notes were used 5 times (0.4% of all FNA cases). Four of the 5 cases were classified as SFN, and 1 was classified as SUS. For 3 of the 4 SFN cases, surgical follow-up was available; 2 of these cases were classified as FVPTC and would currently meet the criteria for NIFTP. Two of these 3 patients underwent total thyroidectomy. The other case, classified as SFN with an FVPTC note, was a follicular adenoma. Finally, in the 1 case called SUS with an FVPTC note, the patient underwent total thyroidectomy and was found to have an invasive FVPTC.
In contrast, during the 1-year study period, NIFTP notes were used 17 times (1.3% of all cases). This included 10 cases classified as SFN with a NIFTP note (SFN-NIFTP) and 7 cases classified as SUS with a NIFTP note (SUS-NIFTP). All FNA cases with a explanatory NIFTP note were reviewed. FNA cases classified as SFN-NIFTP Figure 2 . Representative images from cases in which an explanatory NIFTP note was used. (A,B) Cases classified as suspicious for a follicular neoplasm/follicular neoplasm tended to be cellular with a nearly exclusive microfollicular architecture and some morphologic features of PTC, including slight nuclear enlargement, pallor, and contour irregularity. (C) Although nearly all cases classified as suspicious for malignancy with the explanatory NIFTP note had a significant proportion of groups with a microfollicular architecture and somewhat more pronounced nuclear features of PTC, (D) they also frequently had macrofollicular groups with similar nuclear features. NIFTP indicates noninvasive follicular thyroid neoplasm with papillary-like nuclear features; PTC, papillary thyroid carcinoma.
were almost exclusively composed of microfollicles with diffuse or focal nuclear features of PTC that consisted of mild nuclear enlargement, chromatin pallor, and nuclear contour irregularity ( Fig. 2A,B) . No nuclear pseudoinclusions were identified in any of these cases. Cases diagnosed as SUS-NIFTP had a significant proportion of microfollicles (Fig. 2C ) but also had a substantial number of macrofollicular groups with more pronounced and diffuse PTC-like nuclear changes (Fig. 2D) . There was significant cytomorphologic overlap between cases classified as SFN-NIFTP and SUS-NIFTP, and no morphologic features clearly distinguished these groups.
A NIFTP note was used in 10 of 43 SFN cases (23%) and in 7 of 29 SUS cases (24%). Surgical follow-up was available for 12 of the 17 patients with a NIFTP note (summarized in Table 2 ). Five of 10 SFN-NIFTP patients had surgical follow-up; all proved to have follicularpatterned lesions (4 NIFTP cases and 1 follicular carcinoma). All of the 7 SUS-NIFTP cases had surgical followup. The overall ROM of SUS-NIFTP cases was approximately one-third lower (43%) than the ROM of SUS cases without the note (65%) ( Table 3 ). The majority of SUS-NIFTP cases were follicular-patterned lesions: NIFTP (n 5 2), follicular adenoma (n 5 1), nodular hyperplasia (n 5 1), and invasive FVPTC (n 5 1). However, the remaining 2 cases were classic PTCs. A review of these 2 FNA specimens demonstrated distinct pitfalls. One case showed a predominantly microfollicular-patterned nodule with cytomorphologic features of PTC-nuclear enlargement, pallor, and irregular contours-but lacked papillae, nuclear pseudo-inclusions, or psammoma bodies (Fig. 3A) ; warranting the explanatory NIFTP note. This patient underwent partial thyroidectomy and was found to have a classic PTC on the basis of focal papillary growth that composed less than 10% of the total tumor volume (Fig.  3B ). The second case of classic PTC with a diagnosis of SUS-NIFTP underwent total thyroidectomy due to clinical concern for extrathyroidal extension on imaging studies. In contrast to the prior case, this aspirate consisted mainly of flat sheets of follicular cells with slightly oncocytic cytoplasm, enlarged nuclei with contour irregularity, including grooves, and occasional (>3) nuclear pseudoinclusions (Fig. 3C) . In hindsight, we believe that this case represents an inappropriate application of the NIFTP note and should have been classified as malignant. On excision, this tumor showed diffuse areas of classic PTC with focal tall cell features (Fig. 3D ) and extrathyroidal extension.
We anticipated that a potential NIFTP diagnosis might have the greatest effect on patient management in the SUS category, where the high ROM before the recognition of NIFTP would often prompt surgeons at our institution to perform a total thyroidectomy. It was our hope that explanatory notes for potential NIFTP cases would reduce the number of unnecessary total thyroidectomies. Of the 7 SUS-NIFTP cases during the study period, 5 (71%) underwent partial thyroidectomy. In comparison, for the 16 contemporary SUS cases in the study cohort without the NIFTP note, only 3 (19%) underwent partial thyroidectomy (Table 3) ; a statistically significant decrease in the rate of total thyroidectomy (P < .02; v 2 5 5.9). Of the 26 patients in the control (pre-NIFTP) cohort with a SUS diagnosis, only 3 (12%) underwent partial thyroidectomy; also significantly lower than the rate for the SUS-NIFTP study cases (P < .01; v 2 5 10.7).
All 5 SFN-NIFTP cases with surgical follow-up underwent partial thyroidectomy (100%). In comparison, of the 17 SFN cases without the NIFTP note with surgical follow-up, 14 underwent partial thyroidectomy (82%), and 3 underwent total thyroidectomy. Two of the 3 patients who underwent total thyroidectomy had additional thyroid nodules with indeterminate or malignant cytologic diagnoses. In comparison, in the control group, 17 patients with a SFN diagnosis underwent surgery, and 10 of these patients underwent partial thyroidectomy (59%). These results failed to achieve statistical significance (P 5 .13; v 2 5 2.2).
The proposal to use more stringent criteria for a malignant diagnosis by requiring cytomorphologic features of classic PTC (true papillae, psammoma bodies, and/or frequent pseudo-inclusions) was designed to move cases of NIFTP from the malignant category to the SUS category. One predicted consequence of this increased stringency was a higher proportion of cases of classic PTC with a preoperative SUS diagnosis. Unsurprisingly, we observed such a shift after the adoption of the NIFTP policy (14% vs 26%; Table 4 ) along with the desired decrease in the proportion of noninvasive FVPTC/NIFTP cases in the malignant category (31% vs 17%; Table 4 ). However, given the small number of cases, neither shift was statistically significant (P 5 .14 [v 2 5 2.1] and P 5 .52
[v 2 5 0.42], respectively).
Retrospectively, we identified all FNA specimens from patients with a histologically confirmed NIFTP during the study period (n 5 29). Table 5 shows the preoperative FNA diagnoses associated with each nodule. The great majority of NIFTPs (93%) had an indeterminate cytologic diagnosis. Cases were most frequently classified as AUS (14 cases; 48%), followed by SUS (8 cases; 28%), SFN (5 cases; 17%), benign (1 case; 3%), and malignant (1 case; 3%). Six of these cases (21%) used the NIFTP note (4 SFN cases and 2 SUS cases). In all cases in which the NIFTP note was used, the patients underwent partial thyroidectomy.
One case that was determined to be a NIFTP on excision had a malignant FNA diagnosis. A review of this FNA demonstrated a cellular aspirate consisting of sheets of follicular cells with a macrofollicular architecture, abundant finely granular cytoplasm, and enlarged, irregular, pale nuclei with numerous pseudo-inclusions (Fig. 4A) . On excision, this nodule was a well-circumscribed follicular-patterned tumor that lacked infiltrative growth or lymphovascular invasion (Fig. 4B ) and contained multifocal areas with cytomorphologic features of PTC consistent with a diagnosis of NIFTP, including nuclear pseudoinclusions (Fig. 4C) . Finally, a review of the surgical follow-up from our cohorts demonstrated the change in the malignancy rates associated with each diagnostic category after the introduction of NIFTP (Table 6 ). Similar rates of malignancy were identified in the ND category (1 of 7 cases in both groups; 14%), whereas the rate of malignancy in the benign category decreased from 14% (9 of 65 cases) to 2.2% (1 of 45 cases), the AUS category decreased from 40% (19 of 48 cases) to 20% (9 of 44 cases), the SFN category dropped from 33% (6 of 18 cases) to 18% (4 of 22 cases), the SUS category decreased from 85% (22 of 26 cases) to 61% (14 of 23 cases), and the malignant category dropped from 97% (60 of 62 cases) to 95% (42 of 44 cases). The ROM in the ND, benign, and AUS categories was artificially inflated by the limited number of resections performed on nodules within these groups. If corrected for the total number of ND, benign, and AUS aspirates during the study period, the ROM for these categories would have been 0.9%, 0.1%, and 5.5%, respectively, well within the expected ROM for these categories. 5 
DISCUSSION
The introduction of NIFTP has generated significant interest and uncertainty in the cytology community. The reclassification of noninvasive FVPTC as NIFTP has led several groups to study the anticipated effects on the ROM within TBSRTC. 6, 7 Our study offers early prospective data on the ROM within the TBSRTC framework since the introduction of the NIFTP nomenclature (Table 6 ) and is consistent with the impact predicted by prior retrospective analysis. 6 Although surgery is the appropriate management for a patient with a NIFTP, lobectomy is generally indicated rather than total thyroidectomy. Therefore, it is especially important to identify potential NIFTPs in the SUS and malignant categories, for which total thyroidectomy is often performed. Particularly in the malignant category, the fear of a false-positive diagnosis due to NIFTP could lead cytopathologists to avoid rendering a definitive diagnosis of PTC on FNA altogether.
14 In response to these concerns, we have established a laboratory policy requiring the features of classic PTC (papillae, psammoma bodies, and/or frequent nuclear pseudo-inclusions) that are typically absent in a NIFTP before a malignant for PTC diagnosis is rendered. 12 We have also incorporated explanatory notes into our reports when cytomorphologic features suggest a diagnosis of NIFTP, with a particular goal of highlighting SUS cases that might be more appropriately managed by initial lobectomy. In the year since the adoption of our policy to address NIFTP, our findings indicate that the impact of the policy change at our institution has been minor despite the introduction of more stringent criteria for rendering a malignant for PTC diagnosis. In our cohort, there was no discernible decrease in the use of the malignant category before and after the introduction of the NIFTP terminology (5.2% vs 5.1%, respectively), and the proportions of interpretations as SUS (2.4% vs 2.2%), SFN (2.8% vs 3.3%), and AUS (12% vs 13%) showed minimal changes. We suspect that this lack of significant change reflects several factors: 1) most cases ultimately called NIFTP are recognized as abnormal and are diagnosed in one of the indeterminate TBSRTC categories, 2) features prospectively suggesting the diagnosis of NIFTP are infrequent (1.3% of our cohort), 3) most NIFTPs are not prospectively recognized (only 21% in our series), and 4) most classic PTCs are already readily recognized and distinguished from NIFTPs.
Although the number of cases involved was small, the application of more stringent criteria for a conclusive cytologic diagnosis of PTC appears to have had the desired effect of limiting false-positive diagnoses associated with NIFTP in the malignant category. A single NIFTP with frequent pseudo-inclusions was diagnosed as malignant during the study period, whereas there were 4 malignant cases retrospectively classified histologically as NIFTP in the control period. This refinement of criteria for diagnosing PTC appears to have been at the expense of an apparent slight shift in calling classic PTCs SUS rather than malignant on FNA (11 of 42 classic PTCs after NIFTP vs 7 of 50 before NIFTP; P 5 .14; Table 4 ). These small changes could be due to random fluctuations but are consistent with the anticipated effect of modestly altering the diagnostic criteria for PTC, and although they failed to reach statistical significance in our cohort, these changes may represent a true trend that will become apparent over time. Regardless, the point remains that this change did not result in a dramatic realignment in the diagnosis of PTC in our laboratory. During the study period, the explanatory NIFTP notes were used only 17 times (1.3% of all thyroid FNAs and 5% of all abnormal thyroid FNAs), indicating that the possibility of NIFTP was prospectively entertained in only a small proportion of cases. The use of a NIFTP note had the desired effect on clinical management, with 10 of 12 patients undergoing partial thyroidectomy. It is especially notable that patients with a SUS-NIFTP diagnosis were significantly less likely to undergo total thyroidectomy than contemporary controls who did not get the explanatory note (P < .02) or historical controls (P < .01). Other factors certainly affect surgical management, including family history, nodule size and multiplicity, imaging appearance, and patient and surgeon preferences. In addition, our study period differed from the control period by the intervening publication of the 2015 American Thyroid Association updated clinical management guidelines.
2 Nevertheless, surgical management was similar between the control and study cohorts with the exception of those patients identified in the SUS-NIFTP category. This finding suggests that the use of descriptive language had a strong influence on clinical management in this subset of patients and supports a previous observation that descriptive notes for indeterminate thyroid nodules can have significant effects on patient management. 15 Several groups have suggested that preoperative molecular testing holds promise for refining the ROM in thyroid FNA and may aid in the preoperative identification of NIFTP cases. [16] [17] [18] At our institution, Afirma gene expression testing (Veracyte, Inc, South San Francisco, California) is used in a subset of AUS and SFN cases. Seventeen patients had a SFN-NIFTP or SUS-NIFTP diagnosis, but preoperative molecular testing was performed only for 4 patients within the SFN category. All 4 patients had a gene expression classifier "suspicious" result. Only 1 of these 4 patients had surgical follow-up available with a histologically confirmed NIFTP. Our data reinforce the impression that the prospective distinction of potential NIFTP cases from other diagnoses within the indeterminate categories is challenging. Of the 29 histologically confirmed NIFTP cases during the study period, 27 (93%) were preceded by an indeterminate diagnosis, but only 6 of these (21%) were prospectively recognized as potential NIFTP cases. This low number could be due in part to a failure of vigilance by the pathologist given the change in habit required by the introduction of a new laboratory policy. Conversely, 10 of 12 cases with a NIFTP note (83%) proved to be follicularpatterned lesions, but only 6 (50%) were confirmed histologically as NIFTP.
A potential concern regarding the introduction of an explanatory NIFTP note is overuse for the SUS category; this could result in the undertreatment of patients with a classic PTC, for whom total thyroidectomy might be the preferred initial management. For 1 of the 2 SUS-NIFTP cases that ended up being a classic PTC, the use of the NIFTP note appeared to be appropriate because of the overall cytomorphology of the FNA specimen. Surgical excision in this case showed focal areas (<10% of the tumor volume) with papillary architecture associated with an infiltrative growth pattern precluding the diagnosis of NIFTP and indicating the presence of sampling error in the preceding FNA. Retrospective review of the second case with a SUS-NIFTP diagnosis on cytology indicated that this case had been misclassified because of the presence of definitive cytologic features of PTC, including frequent (>3) nuclear pseudo-inclusions (Fig. 3C) . Notably, this case was not reviewed in consultation within the division or at consensus conference. In both of the preceding cases, correlation with radiologic findings would have indicated that neither nodule likely represented NIFTP. Early studies describing the sonographic features of NIFTP suggest that most NIFTPs appear as hypervascular, well-circumscribed, ovoid/round nodules with variable echogenicity. 19 In our first case of classic PTC with only focal areas of papillary growth on excision, the ultrasound report noted that the nodule was irregularly shaped. More strikingly, the second case of classic PTC with tall cell features and an FNA diagnosis of SUS-NIFTP had sonographic evidence suggestive of extrathyroidal extension, which should have precluded the consideration of a diagnosis of NIFTP. These cases
Original Article suggest that a review of sonographic findings should be performed when one is considering the use of a NIFTP note, particularly within the SUS category, when doing so may prompt a lobectomy, which might represent suboptimal initial management. The 1 NIFTP with a malignant FNA interpretation during the study period (Fig. 4) had classic nuclear features of PTC. This example illustrates that currently recognized cytomorphologic features of NIFTP are not absolute and that rare cases of NIFTP will show some features, such as frequent nuclear pseudo-inclusions, more in keeping with classic PTC. For this reason, we provide the option of an explanatory note for malignant diagnoses that anticipates a decrease in the positive predictive value of a malignant for PTC FNA diagnosis. This note was never used in the year after the introduction of the NIFTP policy. The implemented refinement in the FNA criteria for a malignant diagnosis of PTC may alleviate the need for such a note. Furthermore, as more is learned about NIFTP, cytomorphologic or molecular findings permitting prospective recognition of the exceptional cases diagnosed in the malignant category may be identified.
The explanatory NIFTP note in the cytology report provides clinically useful information to both endocrinologists and surgeons. The note calls attention to the likelihood of an indolent process for which hemithyroidectomy should be considered if there are no high-risk clinical or sonographic features. The addition of the note furthers the process of individualized risk assessment and treatment for thyroid nodules. As illustrated in this study, cytologic findings and risk are interpreted within the larger clinical context, and sonographic evidence of nodule invasion or likely metastatic lymph nodes would prompt a recommendation for total thyroidectomy even if the cytologic features had warranted an explanatory NIFTP note. The integrated approach to thyroid nodule evaluation, incorporating clinical, sonographic, and pathologic data, remains critical to the optimal treatment of thyroid nodules.
In summary, our results suggest that modifying clinical practice to accommodate NIFTP within TBSRTC framework has a modest but important impact on thyroid FNA classification. The use of more stringent criteria for rendering a malignant for PTC diagnosis on FNA does not radically alter the sensitivity of thyroid FNA while potentially minimizing the undesirable diagnosis of NIFTP cases as malignant. Prospective cytologic recognition of a NIFTP is challenging. Nevertheless, when a NIFTP is suspected, particularly in association with a SUS diagnosis, the use of a explanatory NIFTP note promotes appropriate initial surgical management by lobectomy.
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